• NTLA

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study

Intellia Therapeutics' stock fell 20% after Phase 2 results for NTLA-2002 showed improved HAE attack rates, but analysts remain cautious about competitive risks and stock valuation.